SCHEMBL2690873

SCHEMBL2690873

NNC(=O)c1cccc2c1nc(Nc1cccc(Cl)c1)c1ccncc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 14/20 0.81
PIM2 Q9P1W9 14/20 0.81
CSNK2A1 P68400 9/20 0.65
CSNK2A2 P19784 8/20 0.65
CSNK2B P67870 8/20 0.65
CSNK2A3 Q8NEV1 5/20 0.58
CLK2 P49760 3/20 0.58
FLT3 P36888 2/20 0.57
CHEK1 O14757 1/20 0.57
GAK O14976 1/20 0.57
DAPK3 O43293 1/20 0.57
DYRK3 O43781 1/20 0.57
ULK1 O75385 1/20 0.57
STK10 O94804 1/20 0.57
CCNB2 O95067 1/20 0.57
CDK1 P06493 1/20 0.57
CCNB1 P14635 1/20 0.57
PHKG2 P15735 1/20 0.57
CCNE1 P24864 1/20 0.57
CDK2 P24941 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10136796 0.90 PIM1 (1.00) PIM1PIM2CSNK2A1CSNK2A2CSNK2B
SCHEMBL2690272 0.90 PIM1 (1.00) PIM1PIM2CSNK2A1CSNK2A2CSNK2B
SCHEMBL10136809 0.89 PIM1 (0.80) PIM1PIM2CSNK2A1CSNK2A2CSNK2B
SCHEMBL10136804 0.89 PIM1 (0.81) PIM1PIM2CSNK2A1CSNK2A2CSNK2B
SCHEMBL2688882 0.89 PIM1 (1.00) PIM1PIM2CSNK2A1CSNK2A2CSNK2B
SCHEMBL10136798 0.88 PIM1 (0.78) PIM1PIM2CSNK2A1CSNK2A2CSNK2B
SCHEMBL10136802 0.86 PIM1 (1.00) PIM1PIM2CSNK2A1CSNK2A2CSNK2B
SCHEMBL10136792 0.86 PIM1 (1.00) PIM1PIM2CSNK2A1CSNK2A2CSNK2B
SCHEMBL2687706 0.86 PIM1 (1.00) PIM1PIM2CSNK2A1CSNK2A2CSNK2B
SCHEMBL13688144 0.86 PIM1 (0.77) PIM1PIM2CSNK2A1CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
EP-2259678-A1 PROTEIN KINASE MODULATORS Cylene Pharmaceuticals, Inc. (US) 2010-12-15 EP disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885CSNK2A1 680/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885CSNK2A1 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.